These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 15194774)

  • 1. The VP7 outer capsid protein of rotavirus induces polyclonal B-cell activation.
    Blutt SE; Crawford SE; Warfield KL; Lewis DE; Estes MK; Conner ME
    J Virol; 2004 Jul; 78(13):6974-81. PubMed ID: 15194774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies to rotavirus outer capsid glycoprotein VP7 neutralize infectivity by inhibiting virion decapsidation.
    Ludert JE; Ruiz MC; Hidalgo C; Liprandi F
    J Virol; 2002 Jul; 76(13):6643-51. PubMed ID: 12050377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of rotavirus replication by a non-neutralizing, rotavirus VP6-specific IgA mAb.
    Feng N; Lawton JA; Gilbert J; Kuklin N; Vo P; Prasad BV; Greenberg HB
    J Clin Invest; 2002 May; 109(9):1203-13. PubMed ID: 11994409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant Lactobacillus plantarum NC8 strain expressing porcine rotavirus VP7 induces specific antibodies in BALB/c mice.
    Shonyela SM; Shi C; Yang W; Cao X; Yang G; Wang C
    Acta Biochim Biophys Sin (Shanghai); 2021 May; 53(6):707-718. PubMed ID: 33963824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution and phenotype of murine rotavirus-specific B cells induced by intranasal immunization with 2/6 virus-like particles.
    Ogier A; Franco MA; Charpilienne A; Cohen J; Pothier P; Kohli E
    Eur J Immunol; 2005 Jul; 35(7):2122-30. PubMed ID: 15948217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rotavirus-specific cytotoxic T lymphocytes recognize overlapping epitopes in the amino-terminal region of the VP7 glycoprotein.
    Buesa J; Raga JV; Colomina J; de Souza CO; Muñoz C; Gil MT
    Virology; 1999 May; 257(2):424-37. PubMed ID: 10329553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and virus-like particle formation of rotavirus capsid proteins produced in transgenic plants.
    Yang Y; Li X; Yang H; Qian Y; Zhang Y; Fang R; Chen X
    Sci China Life Sci; 2011 Jan; 54(1):82-9. PubMed ID: 21104033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Replication as a determinant of the intestinal response to rotavirus.
    Shaw RD; Hempson SJ
    J Infect Dis; 1996 Dec; 174(6):1328-31. PubMed ID: 8940227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-dependent and -independent protection following intranasal immunization of mice with rotavirus particles.
    McNeal MM; Rae MN; Bean JA; Ward RL
    J Virol; 1999 Sep; 73(9):7565-73. PubMed ID: 10438846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rotavirus vp7 antigen produced by Lactococcus lactis induces neutralizing antibodies in mice.
    Perez CA; Eichwald C; Burrone O; Mendoza D
    J Appl Microbiol; 2005; 99(5):1158-64. PubMed ID: 16238746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solubilized and cleaved VP7, the outer glycoprotein of rotavirus, induces permeabilization of cell membrane vesicles.
    Charpilienne A; Abad MJ; Michelangeli F; Alvarado F; Vasseur M; Cohen J; Ruiz MC
    J Gen Virol; 1997 Jun; 78 ( Pt 6)():1367-71. PubMed ID: 9191931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Particle-bombardment-mediated DNA vaccination with rotavirus VP4 or VP7 induces high levels of serum rotavirus IgG but fails to protect mice against challenge.
    Choi AH; Basu M; Rae MN; McNeal MM; Ward RL
    Virology; 1998 Oct; 250(1):230-40. PubMed ID: 9770437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune responses and protection obtained by oral immunization with rotavirus VP4 and VP7 DNA vaccines encapsulated in microparticles.
    Herrmann JE; Chen SC; Jones DH; Tinsley-Bown A; Fynan EF; Greenberg HB; Farrar GH
    Virology; 1999 Jun; 259(1):148-53. PubMed ID: 10364499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rotavirus-neutralizing antibodies inhibit virus binding to integrins alpha 2 beta 1 and alpha 4 beta 1.
    Fleming FE; Graham KL; Taniguchi K; Takada Y; Coulson BS
    Arch Virol; 2007; 152(6):1087-101. PubMed ID: 17318737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assembly of highly infectious rotavirus particles recoated with recombinant outer capsid proteins.
    Trask SD; Dormitzer PR
    J Virol; 2006 Nov; 80(22):11293-304. PubMed ID: 16971442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rotavirus acceleration of murine type 1 diabetes is associated with increased MHC class I-restricted antigen presentation by B cells and elevated proinflammatory cytokine expression by T cells.
    Pane JA; Webster NL; Zufferey C; Coulson BS
    Virus Res; 2014 Jan; 179():73-84. PubMed ID: 24246305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homotypic and heterotypic serum neutralizing antibody response to rotavirus proteins following natural primary infection and reinfection in children.
    Gorrell RJ; Bishop RF
    J Med Virol; 1999 Feb; 57(2):204-11. PubMed ID: 9892409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rescue of infectivity by sequential in vitro transcapsidation of rotavirus core particles with inner capsid and outer capsid proteins.
    Chen D; Ramig RF
    Virology; 1993 Jun; 194(2):743-51. PubMed ID: 8389080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective efficacy of rotavirus 2/6-virus-like particles combined with CT-E29H, a detoxified cholera toxin adjuvant.
    Siadat-Pajouh M; Cai L
    Viral Immunol; 2001; 14(1):31-47. PubMed ID: 11270595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early response to rotavirus infection involves massive B cell activation.
    Blutt SE; Warfield KL; Lewis DE; Conner ME
    J Immunol; 2002 Jun; 168(11):5716-21. PubMed ID: 12023371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.